← Back to Clinical Trials
Recruiting NCT05748028

NCT05748028 Pain and Autonomic Symptoms in Parkinson's Disease and Atypical Parkinsonisms

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05748028
Status Recruiting
Phase
Sponsor Istituti Clinici Scientifici Maugeri SpA
Condition Parkinson Disease
Study Type OBSERVATIONAL
Enrollment 280 participants
Start Date 2019-06-15
Primary Completion 2026-09-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
RehabilitationAdministration of Clinical scales

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 280 participants in total. It began in 2019-06-15 with a primary completion date of 2026-09-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this observational study is to learn about the impact of the different types of pain and of the domains involved in the autonomic disorders of inpatients and outpatients diagnosed with Parkinson disease (PD) and multiple system atrophy (MSA) admitted to Istituti Clinici Scientifici Maugeri Centers. The main aims are: Evaluate the prevalence of pain and characterize it in Parkinson's disease and atypical parkinsonisms (MSA) Evaluate the effect of rehabilitation on pain and autonomic symptoms Evaluate the prevalence of autonomic symptoms in Parkinson's disease and atypical parkinsonisms (MSA) Assess the impact of pain and autonomic symptoms on quality of life. Participants will perform neurological examination, rehabilitation program and clinical scales. Researchers will compare the two groups of patients (PD and MSA) and the effect of the rehabilitation on pain, autonomic symptoms and quality of life.

Eligibility Criteria

Inclusion Criteria: * Clinical diagnosis of Parkinson's Disease or Multiple System Atrophy according to current international criteria (Gilman S et al, 2008; Postuma RB et al. 2015). * Mini-Mental State Examination score at least 10 Exclusion Criteria: * vascular or pharmacological parkinsonism * diabetes mellitus * hepatic or renal dysmetabolism, * hypothyroidism or hyperthyroidism * assumption of potentially neurotoxic drugs

Contact & Investigator

Central Contact

Maria Nolano, MD, PhD

✉ maria.nolano@icsmaugeri.it

📞 +390824909257

Principal Investigator

Maria Nolano, MD, PhD

PRINCIPAL INVESTIGATOR

Isituti Clinici Scientifici Maugeri SpA SB - IRCCS of Telese Terme

Frequently Asked Questions

Who can join the NCT05748028 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Parkinson Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05748028 currently recruiting?

Yes, NCT05748028 is actively recruiting participants. Contact the research team at maria.nolano@icsmaugeri.it for enrollment information.

Where is the NCT05748028 trial being conducted?

This trial is being conducted at Telese Terme, Italy, Lumezzane, Italy, Castel Goffredo, Italy, Mistretta, Italy and 5 additional locations.

Who is sponsoring the NCT05748028 clinical trial?

NCT05748028 is sponsored by Istituti Clinici Scientifici Maugeri SpA. The principal investigator is Maria Nolano, MD, PhD at Isituti Clinici Scientifici Maugeri SpA SB - IRCCS of Telese Terme. The trial plans to enroll 280 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology